-
1
-
-
0036060499
-
Reference-based pricing schemes: Effect on pharmaceutical expenditure resource utilization and health outcomes
-
Ioannides-Demos L, Ibrahim J, McNeil J. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilization and health outcomes. Pharmacoeconomics 20(9), 577-591 (2002).
-
(2002)
Pharmacoeconomics
, vol.20
, Issue.9
, pp. 577-591
-
-
Ioannides-Demos, L.1
Ibrahim, J.2
McNeil, J.3
-
3
-
-
78650187179
-
Effects of reference pricing in pharmaceutical markets: A review
-
Galizzi MM, Ghislandi S, Miraldo M. Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics 29(1), 17-33 (2011).
-
(2011)
Pharmacoeconomics
, vol.29
, Issue.1
, pp. 17-33
-
-
Galizzi, M.M.1
Ghislandi, S.2
Miraldo, M.3
-
4
-
-
33847333167
-
Reference drug programs: Effectiveness and policy implications
-
Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy 81, 17-28 (2007).
-
(2007)
Health Policy
, vol.81
, pp. 17-28
-
-
Schneeweiss, S.1
-
5
-
-
81755180922
-
European generic medicines association
-
Brussels Belgium
-
European Generic Medicines Association. 2008 Market Review. Brussels, Belgium (2008).
-
(2008)
2008 Market Review
-
-
-
7
-
-
77950450640
-
-
IMS Health IMS Health London UK
-
IMS Health. MIDAS Database. IMS Health, London, UK (2008).
-
(2008)
MIDAS Database
-
-
-
8
-
-
77954886499
-
The impact of reference pricing on the switching behaviour and healthcare utilization: The case of statins in Germany
-
Stargardt T. The impact of reference pricing on the switching behaviour and healthcare utilization: the case of statins in Germany. Eur. J. Health Econ. 11, 267-277 (2010).
-
(2010)
Eur. J. Health Econ.
, vol.11
, pp. 267-277
-
-
Stargardt, T.1
-
9
-
-
26444591589
-
Pharmaceutical policy regarding generic drugs in Belgium
-
Simoens S, De Bruyn K, Bogaert M, Laekeman G. Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeconomics 23(8), 755-766 (2005).
-
(2005)
Pharmacoeconomics
, vol.23
, Issue.8
, pp. 755-766
-
-
Simoens, S.1
De Bruyn, K.2
Bogaert, M.3
Laekeman, G.4
-
10
-
-
33646571919
-
Switch patterns before and after patent expiry of omeprazole: A case study in the Netherlands
-
Klok RM, Boersma C, Oosterhuis I et al. Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands. Aliment. Pharmacol. Ther. 23, 1595-1600 (2006).
-
(2006)
Aliment. Pharmacol. Ther.
, vol.23
, pp. 1595-1600
-
-
Klok, R.M.1
Boersma, C.2
Oosterhuis, I.3
-
11
-
-
81755181778
-
College voor zorgverzekeringen
-
CVZ Diemen The Netherlands
-
College voor zorgverzekeringen. GIP Database. CVZ, Diemen, The Netherlands (2011).
-
(2011)
GIP Database
-
-
-
12
-
-
33644852185
-
Patent drugs in Italy a short-sighted view
-
Garattini L , Ghislandi S. Off-patent drugs in Italy. A short-sighted view? Eur. J. Health Econ. 7, 79-83 (2006).
-
(2006)
Eur. J. Health Econ.
, vol.7
, pp. 79-83
-
-
Garattini, L.1
Ghislandi, S.2
-
13
-
-
34848861325
-
The impact of generic reference pricing interventions in the statin market
-
Puig-Junoy J. The impact of generic reference pricing interventions in the statin market. Health Policy 84, 14-29 (2007).
-
(2007)
Health Policy
, vol.84
, pp. 14-29
-
-
Puig-Junoy, J.1
-
14
-
-
34247531994
-
Antidepressant utilization in primary care in a spanish region impact of generic and reference-based pricing policy 2000-2004
-
Ubeda A, Cardo E, Sellés N, Broseta R, Trillo JL, Fernández-Llimós F. Antidepressant utilization in primary care in a Spanish region. Impact of generic and reference-based pricing policy (2000-2004). Soc. Psychiatry Psychiatr. Epidemiol. 42, 181-188 (2007).
-
(2007)
Soc. Psychiatry Psychiatr. Epidemiol.
, vol.42
, pp. 181-188
-
-
Ubeda, A.1
Cardo, E.2
Sellés, N.3
Broseta, R.4
Trillo, J.L.5
Fernández-Llimós, F.6
-
15
-
-
0042532267
-
The drug budget silo mentality: The DUTCH case
-
Koopmanshap M , Rutten F. The drug budget silo mentality: the Dutch case. Value Health 6(1), 46-51 (2003).
-
(2003)
Value Health
, vol.6
, Issue.1
, pp. 46-51
-
-
Koopmanshap, M.1
Rutten, F.2
-
16
-
-
14844316301
-
Pharmaceutical policy in Italy: Towards a structural change
-
Ghislandi S, Krulichova I, Garattini L. Pharmaceutical policy in Italy: towards a structural change? Health Policy 72, 53-63 (2005).
-
(2005)
Health Policy
, vol.72
, pp. 53-63
-
-
Ghislandi, S.1
Krulichova, I.2
Garattini, L.3
-
17
-
-
61849162196
-
Regulation and pricing of pharmaceuticals: Reference pricing of price cap regulation
-
Brekke K, Grasdal A, Holmås TH. Regulation and pricing of pharmaceuticals: reference pricing of price cap regulation? Eur. Econ. Rev. 53, 170-185 (2009).
-
(2009)
Eur. Econ. Rev.
, vol.53
, pp. 170-185
-
-
Brekke, K.1
Grasdal, A.2
Holmås, T.H.3
-
18
-
-
0036762637
-
Do pharmaceutical prices respond to potential patient out-of-pockets expenses
-
Pavcnik N. Do pharmaceutical prices respond to potential patient out-of-pockets expenses? Rand J. Econ. 33(3), 469-487 (2002).
-
(2002)
Rand J. Econ.
, vol.33
, Issue.3
, pp. 469-487
-
-
Pavcnik, N.1
-
19
-
-
67149137843
-
Effects of the German reference drug program on ex-factory prices of prescription drugs: A panel data approach
-
Augurzky B, Göhlmann S, Gress S, Wasem J. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach. Health Econ. 18, 421-436 (2009).
-
(2009)
Health Econ.
, vol.18
, pp. 421-436
-
-
Augurzky, B.1
Göhlmann, S.2
Gress, S.3
Wasem, J.4
-
21
-
-
33846246421
-
Does therapeutic reference pricing always result in cost-containment the hungarian evidence
-
Kaló Z, Muszbek N, Bodrogi J, Bidló J. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy 80, 402-412 (2007).
-
(2007)
Health Policy
, vol.80
, pp. 402-412
-
-
Kaló, Z.1
Muszbek, N.2
Bodrogi, J.3
Bidló, J.4
-
22
-
-
45449095988
-
Competition in off- patent drug markets: Issues regulation and evidence
-
Kanavos P, Costa-Font J, Seeley E. Competition in off-patent drug markets: issues, regulation and evidence. Econom. Policy 23(55), 499-544 (2008).
-
(2008)
Econom. Policy
, vol.23
, Issue.55
, pp. 499-544
-
-
Kanavos, P.1
Costa-Font, J.2
Seeley, E.3
-
23
-
-
33749529098
-
Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditure interrupted time series analysis of cost volume and cost per volume trends in Sweden 1986-2002
-
Andersson K, Petzold M, Sonesson C, Lönnroth K, Carlsten A. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditure? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy 79, 231-243 (2006).
-
(2006)
Health Policy
, vol.79
, pp. 231-243
-
-
Andersson, K.1
Petzold, M.2
Sonesson, C.3
Lönnroth, K.4
Carlsten, A.5
-
24
-
-
15244359182
-
Reference pricing of pharmaceuticals for medicare: Evidence from germany the netherlands and new zealand
-
Cambridge MA, USA
-
Danzon P, Ketcham J. Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, The Netherlands and New Zealand. National Bureau of Economic Research, Cambridge, MA, USA (2004).
-
(2004)
National Bureau of Economic Research
-
-
Danzon, P.1
Ketcham, J.2
-
25
-
-
78249285572
-
Do generic firms and the Spanish public purchaser respond to consumer price differences of generics under reference pricing
-
Puig-Junoy J , Moreno-Torres I. Do generic firms and the Spanish public purchaser respond to consumer price differences of generics under reference pricing? Health Policy 98, 186-194 (2010).
-
(2010)
Health Policy
, vol.98
, pp. 186-194
-
-
Puig-Junoy, J.1
Moreno-Torres, I.2
-
26
-
-
0034680689
-
Review of the literature on reference pricing
-
López-Casasnovas G , Puig-Junoy J. Review of the literature on reference pricing. Health Policy 54, 87-123 (2000).
-
(2000)
Health Policy
, vol.54
, pp. 87-123
-
-
López-Casasnovas, G.1
Puig-Junoy, J.2
-
27
-
-
63749087204
-
Price control as a strategy for pharmaceutical cost containment - What has been achieved in Norway in the period 1994-2004
-
Håkonsen H, Horn AM, Toverud E-L. Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004? Health Policy 90, 277-285 (2009).
-
(2009)
Health Policy
, vol.90
, pp. 277-285
-
-
Håkonsen, H.1
Horn, A.M.2
Toverud, E.-L.3
-
28
-
-
33846865332
-
Reference prices and generic medicines: what can we expect
-
Mestre-Ferrandiz J. Reference prices and generic medicines: what can we expect? J. Gen. Med. 1(1), 31-38 (2003).
-
(2003)
J. Gen. Med.
, vol.1
, Issue.1
, pp. 31-38
-
-
Mestre-Ferrandiz, J.1
-
30
-
-
33745940233
-
-
Technical Report. Social and Economic Dimensions of an Aging Population Research Papers 71, McMaster University Ontario Canada
-
Grootendorst P, Dolovich L, Holbrook A, Levy A, O'Brien B. The Impact of Reference Pricing of Cardiovascular Drugs on Healthcare Costs and Health Outcomes: Evidence from British Columbia. Volume 2: Technical Report. Social and Economic Dimensions of an Aging Population Research Papers 71, McMaster University, Ontario, Canada (2002).
-
(2002)
The Impact of Reference Pricing of Cardiovascular Drugs on Healthcare Costs and Health Outcomes: Evidence from British Columbia
, vol.2
-
-
Grootendorst, P.1
Dolovich, L.2
Holbrook, A.3
Levy, A.4
O'Brien, B.5
-
31
-
-
0037076037
-
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors
-
Schneeweiss S, Walker A, Glynn R, Maclure M, Dormuth C, Soumerai S. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N. Engl. J. Med. 346(11), 822-829 (2002).
-
(2002)
N. Engl. J. Med.
, vol.346
, Issue.11
, pp. 822-829
-
-
Schneeweiss, S.1
Walker, A.2
Glynn, R.3
Maclure, M.4
Dormuth, C.5
Soumerai, S.6
-
32
-
-
0141483571
-
Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers
-
Schneeweiss S, Soumerai S, Maclure M, Dormuth C, Walker A, Glynn R. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin. Pharmacol. Ther. 74(4), 388-400 (2003).
-
(2003)
Clin. Pharmacol. Ther.
, vol.74
, Issue.4
, pp. 388-400
-
-
Schneeweiss, S.1
Soumerai, S.2
Maclure, M.3
Dormuth, C.4
Walker, A.5
Glynn, R.6
-
33
-
-
77950435775
-
Generic medicine pricing policies in Europe: Current status and impact
-
Dylst P, Simoens S. Generic medicine pricing policies in Europe: current status and impact. Pharmaceuticals 3, 471-481 (2010).
-
(2010)
Pharmaceuticals
, vol.3
, pp. 471-481
-
-
Dylst, P.1
Simoens, S.2
-
34
-
-
33746536484
-
-
Charles River Associates. European Commission Brussels Belgium
-
Charles River Associates. Innovation in the Pharmaceutical Sector. European Commission, Brussels, Belgium (2004).
-
(2004)
Innovation in the Pharmaceutical Sector.
-
-
-
35
-
-
81755189128
-
A call to make valuable innovative medicines available in the european union background report for the ministerial conference 'Innovation and solidarity on pharmaceuticals
-
Brussels Belgium
-
Annemans L, Arickx F, Belle O et al. A call to make valuable innovative medicines available in the European Union. Background report for the ministerial conference 'Innovation and solidarity on pharmaceuticals'. RIZIV/INAMI, Brussels, Belgium (2010).
-
(2010)
RIZIV/INAMI
-
-
Annemans, L.1
Arickx, F.2
Belle, O.3
|